 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH announced that the Centers for Medicare Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT status for the Guardant360 CDx test. The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Under the Protecting Access to Medicare Act of 2014 PAMA, CMS determination confirms that the Guardant360 CDx test meets the 